Cellectis

Brian Busser

Philippe Duchateau

Laurent Poirot

Julien Valton

Alexandre Juillerat

Mohit Sachdeva

The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

Targeted gene insertion for improved immune cells therapy

The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) into genetically engineered immune cells to prevent cytokine release syndrome to arise during the course of cell therapy. These exogenous coding sequences are more particularly soluble human polypeptides placed under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

Targeted gene integration of CRS inhibitor genes for improved immune cells therapy

Targeted gene integration of NK inhibitors genes for improved immune cells therapy

Growing community of inventors

New York, NY, United States of America

Brian Busser